Starling Oncology, Inc. (STLNW) stock

STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 6/30

$0.03+0.00 (+10.87%)

Close on Oct 30, 2026Market cap $665.51MP/E –Yield –

Starling Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Starling Oncology has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Starling Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STLNW.

Revenue growth38.4% · median -2.4%

Operating margin-4.4% · median -6.6%

Net margin-6.2% · median 0.1%

Advertisement
300 × 250